Gene transfer of endostatin enhances the efficacy of doxorubicin to suppress human hepatocellular carcinomas in mice
- 11 July 2007
- journal article
- Published by Wiley in Cancer Science
- Vol. 98 (9), 1381-1387
- https://doi.org/10.1111/j.1349-7006.2007.00542.x
Abstract
Hepatocellular carcinoma (HCC) is one of the most common cancer-related causes of death, and is chemoresistant to anticancer drugs. Anti-angiogenic therapy has been shown to enhance the efficacy of chemotherapy to treat solid tumors. The aim of the present study was to determine whether endostatin, a potent antiangiogenic agent, could enhance the efficacy of doxorubicin to combat HCC. An endostatin expression plasmid was constructed and its expression in vitro and in vivo was detected after gene transfer. Recombinant endostatin inhibited angiogenesis in the chorioallantoic membrane assay, and showed synergistic effects with doxorubicin in inhibiting the in vitro proliferation of endothelial cells, but not that of tumor cells. Both endostatin gene therapy and doxorubicin suppressed the growth of subcutaneous human HepG2 tumors established in BALB/c nude mice, and tumor angiogenesis. Combination therapy with endostatin gene therapy and doxorubicin showed a stronger effect in suppressing tumor growth, and tumor angiogenesis, than the respective monotherapies. Gene transfer of endostatin down-regulated the expression of both hypoxia-inducible factor-1alpha and vascular endothelial growth factor (VEGF), whereas doxorubicin only down-regulated VEGF expression. Endostatin and doxorubicin synergized to down-regulate VEGF expression. Endostatin and doxorubicin combination therapy warrants investigation as a therapeutic strategy to combat HCC.This publication has 38 references indexed in Scilit:
- Systemic Therapy of Advanced Hepatocellular Carcinoma: How Hopeful Should We Be?The Oncologist, 2006
- A Randomized Phase III Study of Doxorubicin Versus Cisplatin/Interferon α-2b/Doxorubicin/Fluorouracil (PIAF) Combination Chemotherapy for Unresectable Hepatocellular CarcinomaJNCI Journal of the National Cancer Institute, 2005
- Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by αvβ3 and α5β1 integrinsProceedings of the National Academy of Sciences, 2003
- Hepatocellular carcinomaThe Lancet, 1999
- Increased growth and incidence of lymph node metastases due to the angiogenesis inhibitor AGM-1470British Journal of Cancer, 1997
- Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor GrowthCell, 1997
- Synergistic effects of TNF-α and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathological, immunohistochemical and electron microscopical studyBritish Journal of Cancer, 1996
- What Is the Evidence That Tumors Are Angiogenesis Dependent?JNCI Journal of the National Cancer Institute, 1990
- Clinical trials in primary hepatocellular carcinoma: current status and future directionsCancer Treatment Reviews, 1988
- Adriamycin treatment for hepatocellular carcinoma experience with 109 patientsCancer, 1985